[{"@type":"ClinicalTrial","_id":"EUCTR2020-001530-35-ES","identifier":"EUCTR2020-001530-35-ES","identifierSource":"EU Clinical Trials Register","url":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001530-35","name":"Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19","alternateName":["Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19"],"abstract":null,"description":null,"sponsor":[{"@type":"Organization","name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital La Paz (FIBHULP)","role":"lead sponsor"}],"author":[{"@type":"Person","name":"Alberto Borobia","affiliation":["Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital La Paz (FIBHULP)"]}],"studyStatus":{"@type":"StudyStatus","status":"authorised","statusDate":"2020-04-20","enrollmentCount":450,"enrollmentType":"anticipated"},"studyEvent":[{"@type":"StudyEvent","studyEventType":"start","studyEventDate":"09\/04\/2020","studyEventDateType":"actual"}],"hasResults":null,"dateCreated":"2020-04-13","datePublished":null,"dateModified":"2020-04-20","curatedBy":{"@type":"Organization","name":"WHO International Clinical Trials Registry Platform","url":"https:\/\/www.who.int\/ictrp\/en\/","versionDate":"2020-05-05"},"healthCondition":["SARS-CoV-2 infection in high-risk contacts","Therapeutic area: Diseases [C] - Virus Diseases [C02]"],"keywords":null,"studyDesign":{"@type":"StudyDesign","studyType":"interventional","phase":["phase 4"],"phaseNumber":[4],"designAllocation":"randomized","designModel":[],"designPrimaryPurpose":null,"studyDesignText":"Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n"},"outcome":[{"@type":"Outcome","outcomeMeasure":"Main Objective: The main objective is to evaluate the efficacy of melatonin in the prevention of SARS-CoV-2 infection in healthcare personnel with high-risk contacts.","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Secondary Objective: o Evaluate the efficacy of melatonin in the prevention of asymptomatic SARS-CoV-2 infections (COVID-19).<br>o To evaluate the efficacy of melatonin in preventing the development of severe COVID-19 in participants who acquire the infection during the development of the study.<br>o Assess the duration of symptoms of COVID-19 infection in participants receiving melatonin.<br>o Assess IgM \/ IgG seroconversion from symptom detection","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Primary end point(s): Number of symptomatic infections confirmed by SARS-CoV-2 (COVID-19)","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Timepoint(s) of evaluation of this end point: 16 weeks","outcomeType":"primary"}],"eligibilityCriteria":[{"@type":"Eligibility","inclusionCriteria":["<br>\u00b7 Men and women aged between 18 and 65 years.<br>\u00b7 They are part of the health personnel of public or private hospitals of the Spanish hospital network in an area with risk of transmission of SARS-CoV-2.<br>\u00b7 Not having been previously diagnosed with SARS-CoV-2 (COVID-19) infection.<br>\u00b7 Have not exhibited symptoms consistent with SARS-CoV-2 (COVID-19) infection from March 1, 2020 until entry into the trial.<br>\u00b7 Understand the purpose of the study and have NOT taken any medications such as PrEP against SARS-CoV-2 from March 1, 2020 until trial entry (also includes PrEP for HIV).<br>\u00b7 Have a negative PCR for SARS-CoV-2 at the entrance.<br>Negative urine pregnancy test performed in the 7 days prior to the start of study treatment in pre-menopausal women or <2 years after menopause.<br>\u00b7 Women of childbearing potential and men of childbearing potential should commit to using a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives or hormonal contraceptive implants) and to continue using them until the day of the last dose. of treatment.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 450<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>"],"exclusionCriteria":["<br>\u2022 HIV infection.<br>\u2022 Active infection with hepatitis B virus.<br>\u2022 Kidney failure (creatinine clearance <60 ml \/ min \/ 1.72 m2) and participants on hemodialysis.<br>\u2022 Osteoporosis.<br>\u2022 Myasthenia gravis.<br>\u2022 Pre-existing maculopathy of the eye.<br>\u2022 Retinitis pigmentosa.<br>\u2022 Bradycardia <50 beats \/ minute.<br>\u2022 Weight <40 Kg.<br>\u2022 Participants with immunosuppressive or hematological disease.<br>\u2022 Treatment in the last month before randomization and for more than 7 days, with drugs that can prolong the QT interval including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone , pentamidine, procaine quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.<br>\u2022 Participants with hereditary galactose intolerance, Lapp lactase deficiency, or glucose or galactose malabsorption.<br>\u2022 Fluvoxamine treatment.<br>\u2022 Treatment with benzodiazepines or non-benzodiazepine hypnotics, such as zaleplon, zolpidem, and zopiclone.<br>\u2022 Pregnancy or planning to become pregnant during the course of the study. Lactation<br>\u2022 Participants with a history of potentially immune-mediated or inflammatory diseases: systemic lupus erythematosus, Crohn's, ulcerative colitis, vasculitis, rheumatoid arthritis.<br>\u2022 Hypersensitivity to the active substance or to any of the excipients.<br>\u2022 Paarticipants who for any reason should not be included in the study according to the evaluation of the research team.<br>"],"gender":"<br>female: yes<br>male: yes<br>"}],"isBasedOn":null,"relatedTo":null,"studyLocation":[{"@type":"Place","studyLocationCountry":"Spain"}],"armGroup":null,"interventions":[{"@type":"Intervention","description":"\nTrade Name: CIRCADIN 2 mg\nProduct Name: CIRCADIN 2mg\nProduct Code: EMEA\/H\/C\/000695\nPharmaceutical Form: Tablet\nINN or Proposed INN: CIRCADIN\nCAS Number: 73-31-4\nOther descriptive name: MELATONIN\nConcentration unit: mg milligram(s)\nConcentration type: equal\nConcentration number: 2-\nPharmaceutical form of the placebo: Tablet\nRoute of administration of the placebo: Oral use","name":"CIRCADIN 2 mg","identifier":"73-31-4"},{"@type":"Intervention","description":""}],"interventionText":"<br>Trade Name: CIRCADIN 2 mg<br>Product Name: CIRCADIN 2mg<br>Product Code: EMEA\/H\/C\/000695<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: CIRCADIN<br>CAS Number: 73-31-4<br>Other descriptive name: MELATONIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>"},{"@type":"ClinicalTrial","_id":"ChiCTR2000030008","identifier":"ChiCTR2000030008","identifierSource":"Chinese Clinical Trial Register","url":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=49426","name":"Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","alternateName":["Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak"],"abstract":null,"description":null,"sponsor":[{"@type":"Organization","name":"The Fifth Affiliated Hospital of Sun Yat-Sen University","role":"lead sponsor"}],"author":[{"@type":"Person","name":"Jing Liu","affiliation":["The Fifth Affiliated Hospital of Sun Yat-Sen University"]}],"studyStatus":{"@type":"StudyStatus","status":"recruiting","statusDate":"2020-02-25","enrollmentCount":100,"enrollmentType":"anticipated"},"studyEvent":[{"@type":"StudyEvent","studyEventType":"start","studyEventDate":"2020-02-12","studyEventDateType":"actual"}],"hasResults":null,"dateCreated":"2020-02-19","datePublished":null,"dateModified":"2020-02-25","curatedBy":{"@type":"Organization","name":"WHO International Clinical Trials Registry Platform","url":"https:\/\/www.who.int\/ictrp\/en\/","versionDate":"2020-05-05"},"healthCondition":["anxiety and depression","novel coronavirus pneumonia (COVID-19)"],"keywords":null,"studyDesign":{"@type":"StudyDesign","studyType":"observational","phase":null,"designAllocation":null,"designModel":["sequential assignment"],"designPrimaryPurpose":null,"studyDesignText":"Sequential"},"outcome":[{"@type":"Outcome","outcomeMeasure":"psychological scale","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Intestinal flora abundance, etc","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Upper respiratory flora abundance, etc","outcomeType":"primary"}],"eligibilityCriteria":[{"@type":"Eligibility","inclusionCriteria":["1. Volunteer to participate in the study and sign informed consent;\r<br>2. Aged 18-65 years, male or female;\r<br>3. Weight >= 40kg and <=100kg, and BMI >= 18kg\/m2;\r<br>4. Medical staff during the novel coronavirus (COVID-19) outbreak."],"exclusionCriteria":["1. Plan for pregnant,breast-feeding or pregnant;\r<br>2. Hospitalized for other reasons within 14 days before the election;\r<br>5. Combined with serious diseases of heart, lung, brain, liver, kidney, blood system;\r<br>6. Has fever, runny nose, diarrhea and other respiratory and digestive symptoms."],"minimumAge":"18","maximumAge":"65","gender":"both"}],"isBasedOn":null,"relatedTo":null,"studyLocation":[{"@type":"Place","studyLocationCountry":"China"}],"armGroup":[{"name":"Nil","@type":"ArmGroup","intervention":[{"name":"Nil","@type":"Intervention"}]}],"interventions":[{"name":"Nil","@type":"Intervention"}],"interventionText":"Case series:Nil;"},{"@type":"ClinicalTrial","_id":"ChiCTR2000029569","identifier":"ChiCTR2000029569","identifierSource":"Chinese Clinical Trial Register","url":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=49062","name":"Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","alternateName":["Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial"],"abstract":null,"description":null,"sponsor":[{"@type":"Organization","name":"Xiangyang 1st People's Hospital","role":"lead sponsor"}],"author":[{"@type":"Person","name":"Pei Bin","affiliation":["Xiangyang 1st People's Hospital "]}],"studyStatus":{"@type":"StudyStatus","status":"not recruiting","statusDate":"2020-02-17","enrollmentCount":30,"enrollmentType":"anticipated"},"studyEvent":[{"@type":"StudyEvent","studyEventType":"start","studyEventDate":"2020-02-05","studyEventDateType":"actual"}],"hasResults":null,"dateCreated":"2020-02-04","datePublished":null,"dateModified":"2020-02-17","curatedBy":{"@type":"Organization","name":"WHO International Clinical Trials Registry Platform","url":"https:\/\/www.who.int\/ictrp\/en\/","versionDate":"2020-05-05"},"healthCondition":["novel coronavirus pneumonia (COVID-19)"],"keywords":null,"studyDesign":{"@type":"StudyDesign","studyType":"interventional","phase":["phase 0"],"phaseNumber":[0],"designAllocation":null,"designModel":["parallel assignment"],"designPrimaryPurpose":null,"studyDesignText":"Parallel"},"outcome":[{"@type":"Outcome","outcomeMeasure":"PSI","outcomeType":"primary"}],"eligibilityCriteria":[{"@type":"Eligibility","inclusionCriteria":["On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4).\r<br>1. patients with severe 2019-ncov according to the clinical stage met any of the following criteria: \r<br>(1) Respiratory distress, RR>=30 times\/min; \r<br>(2) In resting state, oxygen saturation is less than 93%;\r<br>(3) Partial arterial oxygen pressure (PaO2)\/oxygen absorption concentration (FiO2) <=300mmHg (1mmHg= 0.133kpa);\r<br>2. according to the clinical stage of critical 2019-ncov, meet one of the following conditions:\r<br>(1) Respiratory failure occurs and mechanical ventilation is required;\r<br>(2) Shock;\r<br>(3) Combined with other organ failure, intensive care unit is required;\r<br>3. other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient."],"exclusionCriteria":["(1) diseases need to be differentiated from 2019-ncov, such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pulmonary virus, SARS coronavirus and other known viral pneumonia, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia and non-infectious diseases;\r<br>(2) suspected case of 2019-ncov with no confirmed patient;\r<br>(3) the clinical stage was mild: the clinical symptoms were mild, and no pneumonia was observed on imaging;\r<br>(4) clinical stage: common type: fever, respiratory tract and other symptoms, and imaging findings of pneumonia;\r<br>(5) have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;\r<br>(6) other circumstances that the researcher considers inappropriate to participate in this study."],"minimumAge":"18","gender":"both"}],"isBasedOn":null,"relatedTo":null,"studyLocation":[{"@type":"Place","studyLocationCountry":"China"}],"armGroup":[{"name":"Conventional treatment","@type":"ArmGroup","intervention":[{"name":"Conventional treatment","@type":"Intervention"}]},{"name":"conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group","@type":"ArmGroup","intervention":[{"name":"conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group","@type":"Intervention"}]}],"interventions":[{"name":"Conventional treatment","@type":"Intervention"},{"name":"conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group","@type":"Intervention"}],"interventionText":"control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;"},{"@type":"ClinicalTrial","_id":"ChiCTR2000031293","identifier":"ChiCTR2000031293","identifierSource":"Chinese Clinical Trial Register","url":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=51629","name":"Epidemiological study of novel coronavirus infection (COVID-19) in children at medium\/low risk","alternateName":["Epidemiological study of novel coronavirus infection (COVID-19) in children at medium\/low risk"],"abstract":null,"description":null,"sponsor":[{"@type":"Organization","name":"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","role":"lead sponsor"}],"author":[{"@type":"Person","name":"Yan Hao"},{"@type":"Person","name":"Xiaoping Luo"}],"studyStatus":{"@type":"StudyStatus","status":"recruiting","statusDate":"2020-03-30","enrollmentCount":240,"enrollmentType":"anticipated"},"studyEvent":[{"@type":"StudyEvent","studyEventType":"start","studyEventDate":"2020-03-16","studyEventDateType":"actual"}],"hasResults":null,"dateCreated":"2020-03-27","datePublished":null,"dateModified":"2020-03-30","curatedBy":{"@type":"Organization","name":"WHO International Clinical Trials Registry Platform","url":"https:\/\/www.who.int\/ictrp\/en\/","versionDate":"2020-05-05"},"healthCondition":["Novel Coronavirus Pneumonia (COVID-19)"],"keywords":null,"studyDesign":{"@type":"StudyDesign","studyType":"observational","phase":null,"designAllocation":null,"designModel":["sequential assignment"],"designPrimaryPurpose":null,"studyDesignText":"Sequential"},"outcome":[{"@type":"Outcome","outcomeMeasure":"Epidemiological characteristics","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"clinical features","outcomeType":"primary"},{"@type":"Outcome","outcomeMeasure":"Treatment outcome","outcomeType":"primary"}],"eligibilityCriteria":[{"@type":"Eligibility","inclusionCriteria":["Children at medium\/low risk aged 0-18 years who were admitted to the department of pediatrics during the study period"],"exclusionCriteria":["1. Patients at h high risk of SARS-CoV-2 infection;\r<br>2. The guardian does not agree to sign the informed consent or the guardian does not agree to collect information."],"minimumAge":"0","maximumAge":"18","gender":"both"}],"isBasedOn":null,"relatedTo":null,"studyLocation":[{"@type":"Place","studyLocationCountry":"China"}],"armGroup":[{"name":"Nil","@type":"ArmGroup","intervention":[{"name":"Nil","@type":"Intervention"}]}],"interventions":[{"name":"Nil","@type":"Intervention"}],"interventionText":"Case series:Nil;"},{"@type":"ClinicalTrial","_id":"ChiCTR2000031247","identifier":"ChiCTR2000031247","identifierSource":"Chinese Clinical Trial Register","url":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=51540","name":"Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","alternateName":["Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)"],"abstract":null,"description":null,"sponsor":[{"@type":"Organization","name":"West China Hospital, Sichuan University","role":"lead sponsor"}],"author":[{"@type":"Person","name":"Xiandong Meng","affiliation":["West China Hospital, Sichuan University"]}],"studyStatus":{"@type":"StudyStatus","status":"recruiting","statusDate":"2020-03-30","enrollmentCount":500,"enrollmentType":"anticipated"},"studyEvent":[{"@type":"StudyEvent","studyEventType":"start","studyEventDate":"2020-03-01","studyEventDateType":"actual"}],"hasResults":null,"dateCreated":"2020-03-25","datePublished":null,"dateModified":"2020-03-30","curatedBy":{"@type":"Organization","name":"WHO International Clinical Trials Registry Platform","url":"https:\/\/www.who.int\/ictrp\/en\/","versionDate":"2020-05-05"},"healthCondition":["Novel Coronavirus Pneumonia (COVID-19)"],"keywords":null,"studyDesign":{"@type":"StudyDesign","studyType":"observational","phase":null,"designAllocation":null,"designModel":["sequential assignment"],"designPrimaryPurpose":null,"studyDesignText":"Sequential"},"outcome":[{"@type":"Outcome","outcomeMeasure":"mental state","outcomeType":"primary"}],"eligibilityCriteria":[{"@type":"Eligibility","inclusionCriteria":["Medical staff involved in COVID-19 prevention and control."],"exclusionCriteria":["Medical staff without informed consent."],"gender":"both"}],"isBasedOn":null,"relatedTo":null,"studyLocation":null,"armGroup":[{"name":"Nil","@type":"ArmGroup","intervention":[{"name":"Nil","@type":"Intervention"}]}],"interventions":[{"name":"Nil","@type":"Intervention"}],"interventionText":"Case series:Nil;"}]